California Public Employees Retirement System cut its holdings in AnaptysBio Inc (NASDAQ:ANAB) by 1.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 24,800 shares of the biotechnology company’s stock after selling 400 shares during the period. California Public Employees Retirement System’s holdings in AnaptysBio were worth $1,812,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Millennium Management LLC raised its position in AnaptysBio by 11,829.2% in the fourth quarter. Millennium Management LLC now owns 258,624 shares of the biotechnology company’s stock valued at $16,498,000 after purchasing an additional 256,456 shares during the period. BlackRock Inc. raised its position in AnaptysBio by 11.7% in the fourth quarter. BlackRock Inc. now owns 1,816,825 shares of the biotechnology company’s stock valued at $115,894,000 after purchasing an additional 189,685 shares during the period. Advisor Group Inc. purchased a new stake in AnaptysBio in the fourth quarter valued at approximately $7,827,000. Norges Bank purchased a new stake in AnaptysBio in the fourth quarter valued at approximately $7,413,000. Finally, Dimensional Fund Advisors LP purchased a new stake in AnaptysBio in the fourth quarter valued at approximately $5,084,000.

In other news, insider Marco Londei sold 10,060 shares of the company’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $73.06, for a total transaction of $734,983.60. Following the sale, the insider now owns 32,437 shares of the company’s stock, valued at $2,369,847.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Hamza Suria sold 22,428 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $73.76, for a total value of $1,654,289.28. Following the sale, the chief executive officer now directly owns 31,524 shares in the company, valued at approximately $2,325,210.24. The disclosure for this sale can be found here. 14.00% of the stock is currently owned by corporate insiders.

AnaptysBio stock opened at $74.07 on Thursday. AnaptysBio Inc has a twelve month low of $54.26 and a twelve month high of $110.00.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Research analysts predict that AnaptysBio Inc will post -3.63 earnings per share for the current year.

A number of analysts have issued reports on the company. Stifel Nicolaus set a $124.00 target price on AnaptysBio and gave the company a “buy” rating in a research report on Wednesday, May 8th. Zacks Investment Research lowered AnaptysBio from a “buy” rating to a “hold” rating in a research report on Tuesday, May 7th. Cantor Fitzgerald set a $140.00 target price on AnaptysBio and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Wedbush reissued an “outperform” rating on shares of AnaptysBio in a research report on Friday, March 1st. Finally, Guggenheim assumed coverage on AnaptysBio in a research report on Friday, February 22nd. They issued a “buy” rating and a $135.00 target price on the stock. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. AnaptysBio currently has a consensus rating of “Buy” and an average target price of $123.42.

TRADEMARK VIOLATION WARNING: This piece was originally published by Marea Informative and is owned by of Marea Informative. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.mareainformativa.com/news/2019/06/13/anaptysbio-inc-nasdaqanab-position-reduced-by-california-public-employees-retirement-system.html.

About AnaptysBio

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

Featured Story: Candlestick

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).

Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.